HOLXBy Calypso Research6 min read

Hologic (HOLX) Q2 2025 Earnings Analysis

Breast of Show with $1B Revenue Bump

Key Takeaways

Hologic (HOLX) reported Q2 2025 earnings with revenue of $1.0B, representing a +1.2% year-over-year change. The stock moved +2.8% on earnings day.

The bull case: Hologic's strategic shifts in Breast Health and the growing Diagnostics portfolio set the stage for accelerating mid-single-digit revenue growth, supported by a strong outlook for Breast Health and Diagnostics despite some short-term challenges.

The bear case: Tariff impacts, geopolitical challenges, and reliance on mature markets like Breast Health could limit upside in near-term performance, particularly due to headwinds from China and HIV.

Financial Highlights

  • Revenue: $1.0B (+1.2% YoY)
  • Gross Profit: $577M (56.3% margin, +0.9% YoY)
  • Operating Income: $255M (24.9% margin, +0.7% YoY)
  • Net Income: $195M
  • TTM Revenue: $4.0B

Stock Performance

  • Earnings Day Move: +2.8%
  • Year-to-Date: +1.2%
  • 1-Year Return: +16.0%
  • vs. S&P 500 (since earnings): -0.2%
  • vs. Nasdaq (since earnings): -4.5%

View live HOLX data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Hologic's Q2 2025 earnings call:

Breast Health Business Recovery and Gantry Replacement Strategy

Sentiment: Positive

"We see our Breast Health business being even stronger next year than where we'll even finish this year." — Stephen P. MacMillan
"We're absolutely expecting another sequential uptick in the number of gantries... and we have much better visibility at this point in this quarter than we even did in Q3." — Karleen M. Oberton

Diagnostics Business Growth Amid Challenges in China and HIV

Sentiment: Positive

"The headwinds that we are realizing this quarter and next quarter related to China and HIV will also impact the first half of fiscal '26." — Karleen M. Oberton
"The core business of our molecular, our Panthers, the expanding Panthers with our Fusions... we've got a really good short- and mid-term outlook for the Diagnostics business." — Stephen P. MacMillan

Endomag Integration and Growth Trajectory

Sentiment: Positive

"The magic of this business right now... is it's just incredibly steady and growing." — Stephen P. MacMillan
"Endomag expands our portfolio of breast surgery products as we offer additional value across the entire breast cancer continuum of care." — Karleen M. Oberton

Tariff Mitigation and Margin Management

Sentiment: Mixed

"Through changes to our global supply chain and operating model... we expect to mitigate roughly half of the amount we originally provided." — Karleen M. Oberton
"We are expecting a step up Q3 to Q4 in gross margins, starting with the higher gantry portion of the revenue." — Karleen M. Oberton

Role of AI and Fusion in Diagnostics Menu Expansion

Sentiment: Positive

"Fusion uses PCR technology to unlock our full menu of 23-plus assays... we're seeing good traction this year." — Karleen M. Oberton
"Genius transforms the traditional manual review of path slides... enabling a faster, more accurate diagnosis." — Karleen M. Oberton

Bull Case

Hologic's strategic shifts in Breast Health and the growing Diagnostics portfolio set the stage for accelerating mid-single-digit revenue growth, supported by a strong outlook for Breast Health and Diagnostics despite some short-term challenges.

Bear Case

Tariff impacts, geopolitical challenges, and reliance on mature markets like Breast Health could limit upside in near-term performance, particularly due to headwinds from China and HIV.

Looking Ahead

Investors will be closely watching Hologic's next quarterly report for continued execution, particularly around breast Health Business Recovery and Gantry Replacement Strategy. With operating margins at 24.9%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Hologic's revenue in Q2 2025?

Hologic reported Q2 2025 revenue of $1.0B, representing a +1.2% year-over-year change.

Did Hologic beat earnings expectations in Q2 2025?

The stock rose +2.8% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Hologic's strategic shifts in Breast Health and the growing Diagnostics portfolio set the stage for accelerating mid-single-digit revenue growth, supported by a strong outlook for Breast Health and Diagnostics despite some short-term challenges.

What is the bull case for HOLX stock?

The bull case for HOLX centers on: Hologic's strategic shifts in Breast Health and the growing Diagnostics portfolio set the stage for accelerating mid-single-digit revenue growth, supported by a strong outlook for Breast Health and Diagnostics despite some short-term challenges.

What is the bear case for HOLX stock?

The bear case for HOLX centers on: Tariff impacts, geopolitical challenges, and reliance on mature markets like Breast Health could limit upside in near-term performance, particularly due to headwinds from China and HIV.

How has HOLX stock performed since its Q2 2025 earnings?

HOLX moved +2.8% on the day of its Q2 2025 earnings report, underperforming the S&P 500 by +0.2% since earnings. Year-to-date, the stock has returned +1.2%.

Browse all 400+ earnings reports →

Learn More

Analyze HOLX in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Hologic and 400+ other stocks, explore the full platform.

Open HOLX on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.